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Background & Aim: 32	  
Critically ill patients are regularly feed via constant enteral (EN) nutrition infusions. 33	  
However, the incretin effect or its impact on endogenous insulin concentration remains 34	  
unclear. This study determines whether there is an EN-driven incretin effect in critically ill 35	  
patients requiring glycaemic control. 36	  
Methods: 37	  
Clinically validated, model-based time-variant insulin sensitivity (SI) profiles were identified 38	  
for 52 non-diabetic patients on Specialized Relative Insulin Nutrition Titration (SPRINT) 39	  
glycemic control during transitions off EN (ON/OFF), and back on to EN (OFF/ON). Incretin 40	  
effects were observable via increased modelled SI after the OFF/ON transition or a decreased 41	  
SI after the ON/OFF transition.   42	  
Results: 43	  
Patients exhibited a median -36% (IQR -82% to 24% p=0.001) reduction after the ON/OFF 44	  
feed transition, and a median of +32% (IQR -5% to 53%, p=0.05) rise in measured SI after 45	  
the OFF/ON transition. However, 32% of patients exhibited increased SI at the OFF/ON 46	  
transition, and 37% exhibited reduced SI at the ON/OFF transition. The results are likely due 47	  
to changes in patient condition over the 5-8 hours considered outweighing this effect. Blood 48	  
glucose was the same during both transitions with median shifts of -2% and -3% after the 49	  




Results imply a significant incretin effect is observed at a cohort level. The impact was 52	  
stronger for the OFF/ON transition indicating that this effect may be blunted by long-term 53	  
continuous EN infusions. These results provide the data to design conclusive studies, and to 54	  
inform glycemic control protocol development and implementation. 55	  
 56	  
Keywords: incretin effect, enteral nutrition, insulin sensitivity, Specialized Relative Insulin 57	  




1. Introduction 60	  
 61	  
Critically ill patients exhibit increased gluconeogenesis, reduced insulin secretion and 62	  
increased insulin resistance, resulting in hyperglycemia, increased complications and 63	  
increased risk of death.1-­‐2 Studies show that glycemic control can reverse these outcomes.2-3 64	  
However, intensive insulin therapy can also lead to increased hypoglycaemia and mortality.4-5 65	  
Variable patient-specific levels of endogenous insulin secretion may also play a role, 66	  
particularly in early, acute phases of care.5 In addition, the route used for the provision of 67	  
nutrition can also influence the effect of intensive insulin therapy on outcome. A recent meta-68	  
analysis6 demonstrated that intensive insulin therapy was not associated with an improved 69	  
outcome when enteral nutrition was used as the predominant source of calories. This finding 70	  
is consistent with the presence of an incretin effect, i.e. the stimulation of endogenous insulin 71	  
by enteral feeding. 72	  
 73	  
The incretin effect plays an important role in regulation of glucose metabolism in healthy 74	  
subjects.7 Incretin enhances the postprandial appearance of insulin. The underlying 75	  
mechanisms involve the release of the hormones glucose-dependent insulinotropic 76	  
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which are released from the 77	  
intestinal mucosa when glucose is ingested. As a result insulin secretion is enhanced in 78	  
excess of what would have been released if the glucose were administered parenterally.8 79	  
Studies have shown that the incretin effect can enhance the insulin response to oral glucose 80	  




Although many incretin effect studies have addressed the distinct physiology of diabetic and 83	  
non-diabetic individuals,9 the incretin effect remains to be observed in a critically ill cohort.  84	  
 85	  
Critically ill patients are fed differently, typically relying on constant enteral (EN) infusions. 86	  
Hence, it is possible that there is no incretin effect in these patients, who otherwise display 87	  
significantly enhanced endogenous insulin secretion.11 Equally, their highly counter-regulated 88	  
state and wide range of insulin secretion rate1 may result in a blunting of this responses as 89	  
seen similarly in individuals with type 2 diabetes.9  90	  
 91	  
This study uses dense clinical data and a model-based analysis to observe the incretin effect 92	  
via tracking the model-based insulin sensitivity (SI) in a cohort of critically ill patients. 93	  
Specifically, we hypothesized that model-based SI would fall during interruptions of EN and 94	  
would rise when EN is re-started. These changes in SI would support the presence of an EN-95	  
related incretin effect in the population of non-diabetic critically ill patients studied.  96	  
 97	  
2. Methods 98	  
2.1. Patient cohort 99	  
 100	  
The data used in this paper was obtained from the Specialized Relative Insulin Nutrition 101	  
Titration (SPRINT) study.12 Blood glucose concentration (BG) and enteral (EN) nutrition 102	  
data from 371 critically ill patients on SPRINT study are used. These 371 patients were 103	  
undergoing SPRINT tight glycaemic control (TGC), with 97% of patients had 50% or more 104	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of their BG within a 4.0 to 7.0 (mmol·L-1)	   , where insulin and nutrition are given in balance 105	  
based on estimated response to the prior insulin and nutrition intervention.13 Hence, the 106	  
protocol will prevent hyperglycaemia by matching the nutrition and exogenous insulin given 107	  
to the body’s patient-specific ability to utilise them. Full details on this study can be obtained 108	  
from Chase et al. (2008).14 Specifically, the study inclusion required a minimum of 10 hours 109	  
of EN feeding, followed by at least 7 hours with EN off, and then at least 5 hours of resumed 110	  
feeding. Hence, only 52 of 371 SPRINT patients’ data were selected based on these criteria.  111	  
Patients with diabetes (N=64) were also excluded due to irregularity of the incretin effect that 112	  
is known to occur in diabetes.9-10 This study omitted 255 further, non-diabetic patients as they 113	  
did not have a period of zero EN input. 114	  
  115	  
The clinical details of this cohort, including baseline variables, Acute Physiology and 116	  
Chronic Health Evaluation (APACHE) II scores and APACHE III diagnosis codes are 117	  
summarized in (Table 1). Data from the excluded non-diabetic patients (N=255) is added for 118	  
comparison. 119	  
 120	  
Table 1  121	  
 122	  
The transition off EN (ON/OFF) is defined when EN nutrition given to the patient is stopped, 123	  
while the (OFF/ON) transition when EN is started again. These times are known to within 124	  
±30 minutes from chart data. The glucose input from EN infusion varies from 0 to 1.65 125	  
(mmol·min-1) where the range of patient-specific goal nutrition rates is 0.4 (mmol·min-1) to 126	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0.8 (mmol·min-1).12 The compositions of EN were either from Glucerna® 1.2 CAL (Abbott)15 127	  
or RESOURCE® Diabetic (Novartis)16. The nutritional compositions are given in (Table 2). 128	  
 129	  
Table 2  130	  
 131	  
2.2. Identification of Model-Based SI 132	  
 133	  
Model-based SI is identified assuming constant endogenous insulin secretion as secretion 134	  
cannot be directly measured at bedside. This assumption is required to measure the presence 135	  
of an incretin effect with an increased modelled SI after the ON/OFF feed transitions. SI(t) is 136	  
identified hourly using integral-based methods17 and clinical data.  137	  
The clinically validated Intensive Control Insulin-Nutrition-Glucose (ICING) model 138	  
presented by Lin et al.18 is used to measure SI hourly from each patient’s clinical data: 139	  
 (1) 140	  
      (2) 141	  
    (3) 142	  
where: BG (mmol·L-1) denotes the glucose above an equilibrium level, I and Q are plasma 143	  
and interstitial insulin, respectively (mU·L-1), exogenous insulin is uex(t) (mU·min-1), nI (min-144	  
1) defines the diffusion constant of insulin between compartments, and nC (min-1) is the 145	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cellular insulin clearance rate from interstitium. Patient endogenous glucose removal and 146	  
insulin sensitivity are pG (min-1) and SI (L·mU-1·min-1), respectively, glucose and insulin 147	  
distribution volume are VG (L) and VI (L), Michaelis-Menten functions are used to portray 148	  
saturations, with αI (L·mU-1) dictating the saturation of plasma insulin clearance, and αG 149	  
(L·mU-1) for saturation of insulin-mediated glucose removal, nK (min-1) and nL (min-1) are the 150	  
renal and hepatic insulin clearance rates, respectively, xL is the first pass hepatic clearance 151	  
ratio19, while uen is the endogenous insulin production (1000 mU·min-1).  152	  
Enteral nutrition (EN), P(t) is defined with Equations 4-6: 153	  
           (4) 154	  
       (5) 155	  
       (6) 156	  
 157	  
where: P1 and P2 (mmol) represent the glucose in the stomach and gut, respectively, P(t) is 158	  
the glucose appearance in plasma (mmol·min-1) from enteral nutrition. The parameters d1 and 159	  
d2 are used to describe the rate of glucose transport through the enteral route into the 160	  
bloodstream. These parameters are assumed constant across the cohort (d1 = 0.0347 min-1 and 161	  
d2 = 0.0069 min-1),18 whereas both parameters can vary significantly between individuals, 162	  
potentially affecting description of transient changes in plasma glucose appearance after 163	  
changes in EN feeding, and thus the modelling of SI. The rate of transport from P2 is limited 164	  
to the maximal gut glucose flux (Pmax = 6.11 mmol·min-1), and also D(t) represents the 165	  




This model has been clinically validated with median prediction error less than 4-5%18 and is 168	  
currently used in several clinical glycaemic control trials.20-21 169	  
 170	  
2.3. Data Analysis  171	  
 172	  
A reduction in observed SI after the ON/OFF transition implies an un-modelled decrease in 173	  
the rate of endogenous insulin production due to incretin effects. In contrast, an increase in 174	  
observed SI implies an incretin effect at the OFF/ON transition. The SI change (ΔSI) across 175	  
the ON/OFF and OFF/ON transitions indicates an incretin effect for this cohort. ΔSI was 176	  
calculated as:  177	  
     (7) 178	  
The blood glucose changes, ΔBG were also calculated similar to the ΔSI.  179	  
 180	  
The analysis uses a 3-hour moving average to reduce the effect of measurement error, noise, 181	  
and the influence of transient effects caused by the cohort-constant assumption of these 182	  
model terms. SI profiles are derived over periods starting 3 hours before a transition until 5 183	  
hours after the transition. The 5-hour limit allows full gut emptying after ON/OFF transition 184	  
or full resumes of the effect EN after the OFF/ON transition. Between these times, an incretin 185	  
effect would show a steady biased shift in SI, if it exists. Results are illustrated via Bland – 186	  
Altman plots, while Wilcoxon rank sum tests are used to compare distributions and the 187	  




3. Results 190	  
 191	  
Measured glucose data, EN model input data as well as ICING model fits of BG, I, Q, SI and 192	  
P are shown in (Fig. 1) for a typical case. The incretin effect is observed directly via insulin 193	  
sensitivity changes (ΔSI) at ON/OFF and OFF/ON transitions.  194	  
 195	  
Fig. 1.  196	  
 197	  
(Table 3) summarises ΔSI at the ON/OFF transition across the cohort. SI decreased after the 198	  
ON/OFF transition until t=+4 hours, where it settled to a median reduction of -36%. The 199	  
right-most column shows the number of confounders (ΔSI>0). This implies that inter-patient 200	  
or intra-patient variation obscures the observation or that the effect itself it is not always 201	  
observable. ΔSI data after the OFF/ON transition are shown in (Table 4). Median ΔSI 202	  
increased by +32% (IQR -1 to 60%) at t=+3 hours after the OFF/ON feed transition. The 203	  
number of confounders was slightly lower after the OFF/ON feed transition. In both cases, 204	  
BG remains effectively constant with only small changes. Hence, the impact of the incretion 205	  
effect on glycaemia was quickly accounted for by the SPRINT glycaemic control protocol. 206	  
  207	  
Table 3 208	  
  209	  




SI correlations over the ON/OFF (r=0.49, median=-36%, p=0.0001) and OFF/ON (r=0.60, 212	  
median=+31%, p=0.03) transitions for t=+4 hours are shown in (Fig. 2). The changes in 213	  
(Table 3–4) are evidenced by the bias about the equality line. (Fig. 2) shows the diversity of 214	  
ΔSI across both transitions.  215	  
 216	  
Fig. 2.  217	  
 218	  
Fig. 3.  219	  
 220	  
Bland-Altman representations of the ΔSI changes between t=-2 and t=+4 hours are shown in 221	  
(Fig. 3). Only 3 patients clearly showed high ΔSI measurements (>100%). These patients 222	  
were diagnosed with either sepsis or pancreatitis. Both conditions significantly affect 223	  
endogenous insulin secretion independently. Most changes show a clear shift with relatively 224	  
consistent behaviours. 225	  
 226	  
Fig. 4.  227	  
 228	  
Bland-Altman representations the shifts in BG after the ON/OFF and OFF/ON transitions 229	  
between t= -2 and t=+4 hour’s are shown in (Fig. 4). The maximal median BG shift across the 230	  
cohort was -4% at the ON/OFF transition and +6% at the OFF/ON transition when t=+3 and 231	  
t=+4 respectively. Median difference between these two transitions was approximately -1% 232	  
at t=-1, +1, and +2 indicating tight consistent glucose levels across the cohort. The few 233	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patients outside the 90% confidence interval (CI) were identified as having pancreatitis or 234	  
similar diseases that significantly affect insulin secretion and thus, this analysis. 235	  
 236	  
4. Discussion 237	  
 238	  
This study showed the potential existence of an incretin effect after EN transitions (ON/OFF 239	  
and OFF/ON) in a cohort with similar controlled BG levels. The incretin effect was observed 240	  
via changes in model-based SI after transitions onto and off EN feed. This effect has been 241	  
previously observed using different techniques in various, non-critically ill cohorts.22 In this 242	  
study, a slightly stronger incretin effect is observed at OFF/ON EN feed transition.  243	  
 244	  
The changes in plasma insulin via insulin secretion and activation by the liver were assumed 245	  
to be observable through changes in measured SI.18 The variability observed was outside the 246	  
normal variation, which is centred around zero.23 Thus, the incretin effect was measured 247	  
using the shift in SI after EN feed transitions as a surrogate rather than direct insulin 248	  
measurement. Nauck et al.10 found that C-peptide responses after oral and intravenous 249	  
glucose were less marked than between insulin responses. This implies that a considerable 250	  
part of the different insulin responses to oral and intravenous glucose may be due to altered 251	  
hepatic insulin extraction.24 Thus, it could be concluded that insulin sensitivity changes are 252	  
more efficient indicator for post-hepatic endogenous insulin appearance,10 given the two 253	  
possible outcome causes noted. A further study to confirm these findings could be verified 254	  




ΔBG changes were insignificant over these transitions indicating there was no bias to this 257	  
factor in the model-based analysis. Equally, this model and SI metric have been clinically 258	  
validated on independent matched cohorts,13 in several clinical TGC studies,12 and against the 259	  
gold-standard  euglycaemic clamp.25  260	  
 261	  
The insulin response to EN glucose was noticeably enhanced after the OFF/ON transition, 262	  
most likely as a result of the concomitant actions of incretins and neural responses to enteral 263	  
nutrition. The predominant effect of incretin hormones is to enhance the endogenous insulin 264	  
secretion that is triggered when the β-cells are exposed to rapid increases in glucose flux.24 At 265	  
a cohort level, ΔSI stabilised at t=+4 hours after EN transitions as the feed was designed for 266	  
enhanced glycaemic stability via slow digestion.15-16 Hence, both transitions should have 267	  
excited a change, but the OFF/ON transition may have observed better or more rapid change 268	  
due to the essentially fasted patient state.  269	  
 270	  
The Bland-Altman plots of ΔSI (Fig. 3) show that the few larger outliers were diagnosed with 271	  
chronic diseases that influence the pharmaco-dynamics of insulin and glucose. Patients with 272	  
sepsis, trauma or pancreatitis can exhibit more drastic SI changes26 due to excessive counter-273	  
regulatory and acute immune response, as well as the direct affect on secretion with 274	  
pancreatitis. Hence, the variability of results was reasonably expected, where the analysis 275	  
without these 3-5 subjects did not change the overall results. Also, studies show that many 276	  
metabolic abnormalities associated with stress, injury or infections were related to a loss of 277	  
tissue sensitivity to insulin.26 Sepsis, trauma and other clinical states are characterized by a 278	  
strong counter-regulatory hormone response. These hormone responses are believed to 279	  
induce insulin resistance in vivo, although some clinical studies failed to demonstrate 280	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correlations between the counter-regulatory hormone response and defective insulin-mediated 281	  
glucose disposal.27 However, the overall evidence is still inconclusive concerning the exact 282	  
cellular and molecular mechanisms underlying insulin resistance in critical illness and their 283	  
relationship to the observed metabolic abnormalities.27  284	  
 285	  
Specifically, this analysis consists of a group selected from a general ICU cohort (see Table 1 286	  
with a representative mixture of typical ICU diagnostic codes) who met the criteria that 287	  
would enable the incretin effect to be observed in this study if the effect existed. It is not 288	  
designed, as a trial to guarantee representation of any specific ICU cohort in particular. 289	  
However, as seen in Table 1 the groups are similar in age and severity of illness compare to 290	  
the remaining (non-diabetic) SPRINT cohort from which these 52 were extracted. The 291	  
diagnostic groupings are less similar but still broadly represent a medical ICU cohort. Hence, 292	  
the cohort analysed were not different from the overall SPRINT cohort or a typical medical 293	  
ICU cohort, except in that they had nutritional stoppages for clinical reasons that enabled this 294	  
study. Thus, these results justify a more direct clinical validation trial with measurement of 295	  
insulin, C-peptide and incretin hormones during enteral and parenteral feed transitions. This 296	  
may provide direct evidence of the incretin effect observed in this study and also provide 297	  
enough data to allow generalisation of the result for broader cohorts. These results are 298	  
sufficient to justify and define the needed cohort size to power such a validation trial. . 299	  
 300	  
It is generally accepted that intravenous parenteral nutrition (PN) prompts a lesser 301	  
endogenous insulin secretion than EN nutrition,9 and thus may limit the incidence of 302	  
hypoglycaemia due to un-modelled insulin secretion. Plasma insulin responses to glucose 303	  
given by gastric or jejunal intubation were significantly greater than those seen after IV 304	  
16 
 
infusion of the same glucose load in some studies.8 Likewise, Petrov et al.28 reported a higher 305	  
prevalence of hyperglycemia during parenteral than enteral nutrition. Hence, if the risk of 306	  
hypoglycaemia could be mitigated via advanced modelling methodology, the potential 307	  
benefits of the incretin effect could aid patient recovery. In addition, enteral nutrition is also 308	  
associated with a significantly lower incidence of infection, sepsis and bacterial translocation 309	  
that may reduce the need for surgical interventions to control pancreatitis and a reduced 310	  
length of hospital stay.29  311	  
 312	  
This study examined changes in SI about EN feeding transitions. Limited PN data (N<6) 313	  
somewhat limited observation of the incretin effect with EN according to its most commonly 314	  
used definition in comparison to PN.30 In this study, the SPRINT glycaemic control protocol 315	  
also modulates enteral dextrose carbohydrate to aid control of hyperglycaemia, rather than 316	  
the characterising the overall nutritional profile. Hence, a cross-over analysis with PN was 317	  
not possible. A study conducted by Van den berghe et al.31 found that a high glucose loading, 318	  
via PN, with inadequate glycemic control is associated with increased morbidity and 319	  
mortality rates. Thus, an ideal study design for the observation of incretin in critically ill 320	  
patients that also used PN feeding in a cross-over format might have ethical limitations. In 321	  
contrast, future studies could incorporate direct measurement of incretin hormones, such as 322	  
GIP and GLP-1.9 This approach would also allow direct incorporation and identification of 323	  
additional incretin hormone-related model parameters, as well as direct measurement of the 324	  
effect without relying on PN analysis. 325	  
 326	  




Overall, the findings of this study show the distinct existence of an incretin effect as an 329	  
observable aspect of critically ill patient physiology. The findings were consistent with the 330	  
presence of an EN-related incretin effect in a majority of critically ill patients. Clinically, the 331	  
existence of this effect at EN nutrition transitions should also be considered in the 332	  
management of glycaemia and could influence design of this therapy. Finally, while the 333	  
results observed valid surrogates of the incretin effect, a prospective study with direct 334	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Figure legends 445	  
 446	  
Fig. 1. A typical patient’s fitted profile. (A) Blood glucose, plasma insulin and interstitial 447	  
insulin fitted profiles (B) EN rate (C) Time variant insulin sensitivity (SI).  448	  
 449	  
Fig. 2. The distributions of SI for two EN transitions of ON/OFF (A) and OFF/ON (B) EN 450	  
transitions at the centred time averages of t=-2 and t=+4 hours (N=52). (Note the log-scale). 451	  
 452	  
Fig. 3. The Bland-Altman of the averages of proportional change SI after the ON/OFF (A) 453	  
and OFF/ON (B) EN transitions at the centred time averages of t=-2 and t=+4 hours (N=52).  454	  
 455	  
Fig. 4. The Bland-Altman of the averages of proportional change BG after ON/OFF (A) and 456	  
OFF/ON (B) EN transitions at the centred time averages of t=-2 and t=+4 hours (N=52). 457	  
 458	  
  459	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Patient Data from SPRINT 
 Excluded, Non-
Diabetic Cohort 
Included Cohort  
 N=255 *N=52  
Age (years) 65 [51-74] 65 [49-72] p=0.86 
% Male 70% 67%  
APACHE II score 18 [14-23] 19 [17-28] p=0.07 
    
APACHE III 
Diagnosis 
Number of Patients (%) 
 
   Cardiovascular 38 (15%) 5 (10%)  
   Respiratory 64 (25%) 8 (15%)  
Pancreatitis 11 (4%) 7 (13%)  
   Neurological 21 (8%) 6 (12%)  
   Trauma 38 (15%) 6 (12%)  
   Sepsis 12 (5%) 7 (13%)  
   Other 
   (Renal, metabolic,  
    orthopaedic) 
71 (28%) 13 (25%)  
*N=52 are the patient data used in this study. Note N=255 and N=52 exclude diabetic data. 
Table 1 SPRINT Cohort baseline variables for included patients and non-diabetic excluded 460	  
patients. Data are expressed as median [IQR]. (APACHE = Acute Physiology and Chronic 461	  
Health Evaluation). 462	  
	  463	  









16 g/1000 mL 
36 % 
12 g/1000 mL 
Protein 20 % 24 % 
Fat 45 % 40 % 
 466	  
Table 2 Enteral nutrition composition based on GLUCERNA® 1.2 CAL and RESOURCE® 467	  









Blood Glucose (ΔBG) Insulin Sensitivity (ΔSI) 
Median IQR p-value Median IQR p-value SI (↑) 
-2 0% [0,0]% 1.0 0% [0,0] 1.0 50% 
-1 0% [-3,6]% 1.0 0% [-10,12]% 0.9 50% 
0 -1% [-9,5]% 0.7 -2% [-16,18]% 0.7 46% 
+1 -2% [-12,8]% 0.6 -9% [-30,23]% 0.3 38% 
+2 -1% [-12,9]% 0.6 -10% [-45,15]% 0.05 27% 
+3 -4% [-15,10]% 0.5 -29% [-59,15]% 0.01 29% 
+4 0% [-16,17]% 0.4 -36% [-82,24]% 0.001 37% 
 471	  
Table 3 Summary of proportional change of blood glucose (ΔBG) and insulin sensitivity, 472	  
(ΔSI) at ON/OFF feed transition (N=52). (*times are 3-hour averages centred at the time 473	  










Blood Glucose (ΔBG) Insulin Sensitivity (ΔSI) 
Median IQR p-value Median IQR p-value SI (↓) 
-2 0% [0 0]% 1.0 0% [0 0]% 1.0 50% 
-1 -1% [-6,2]% 0.6 4% [-13,12]% 0.9 39% 
0 -1% [-9,6]% 0.9 8% [-14,23]% 0.9 40% 
+1 -3% [-11,7]% 0.6 14% [-5,29]% 0.5 33% 
+2 -2% [-10,15]% 0.9 25% [-10,46]% 0.3 29% 
+3 1% [-12,15]% 0.7 32% [-5,53]% 0.05 32% 
+4 6% [-15,18]% 0.5 31% [-1,60]% 0.03 25% 
 478	  
Table 4 Summary of proportional change of blood glucose (ΔBG) and insulin sensitivity, 479	  
(ΔSI) at OFF/ON feed transition (N=52). (*times are 3-hour averages centred at the time 480	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